Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment (vol 12, pg 134, 2010)

被引：7
|
作者：
Hecker, M.
Goertsches, R. H.
Fatum, C.
Koczan, D.
Thiesen, H-J
Guthke, R.
Zettl, U. K.
机构：
来源：
PHARMACOGENOMICS JOURNAL | 2012年 / 12卷 / 04期
关键词：
D O I：
10.1038/tpj.2011.12
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Correction to: The Pharmacogenomics Journal (2012) 12, 134–146; doi:10.1038/tpj.2010.77 Elements were omitted from the Supplementary Information that accompanied the online version of this article. For Supplementary Table 1, the following information should have been included: ‘A list of 121 genes up- or downregulated during first 4 weeks of intramuscular IFN-β-1a treatment.
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [31] ECONOMIC EVALUATION OF FINGOLIMOD COMPARED TO INTERFERON-β1A IN THE TREATMENT OF PEDIATRIC-ONSET MULTIPLE SCLEROSIS (POMS) IN MEXICO
    Tierrablanca, L.
    Gonzalez, L. A.
    Botello, B. S.
    Gomar, D.
    VALUE IN HEALTH, 2020, 23 : S266 - S267
  • [32] Gene expression patterns identify short-term interferon-β-1a (Rebif) treatment effects in multiple sclerosis
    Achiron, A.
    Snir, Y.
    Magalashvili, D.
    Feldman, A.
    Sonis, P.
    Gurevich, M.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 205 - 205
  • [33] Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada
    Nakhaipour, Hamid Reza
    Vudumula, Umakanth
    Khurana, Vivek
    Sebire, Guillaume
    Mah, Jean K.
    Pohl, Daniela
    Schecter, Robyn
    Adlard, Nicholas
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1525 - 1533
  • [34] The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis
    Visser, Laurenske A.
    Folcher, Marc
    Delgado Simao, Claudia
    Gutierrez Arechederra, Biotza
    Escudero, Encarna
    Uyl-de Groot, Carin A.
    Redekop, William Ken
    PHARMACOECONOMICS, 2022, 40 (01) : 91 - 108
  • [35] Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
    Gurevich, Michael
    Miron, Gadi
    Falb, Rina Zilkha
    Magalashvili, David
    Dolev, Mark
    Stern, Yael
    Achiron, Anat
    BMC NEUROLOGY, 2015, 15
  • [36] Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
    Michael Gurevich
    Gadi Miron
    Rina Zilkha Falb
    David Magalashvili
    Mark Dolev
    Yael Stern
    Anat Achiron
    BMC Neurology, 15
  • [37] Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis (vol 14, pg 259, 2008)
    Serarslan, Gamze
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (09) : 1303 - 1303
  • [38] In vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsing-remitting multiple sclerosis
    Losy, J
    Michalowska-Wender, G
    ACTA NEUROLOGICA SCANDINAVICA, 2002, 106 (01): : 44 - 46
  • [39] Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis (vol 39, pg 285, 1996)
    Jacobs, LD
    ANNALS OF NEUROLOGY, 1996, 40 (03) : 480 - 480
  • [40] Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis -: An econometric model
    Lepen, C
    Coyle, P
    Vollmer, T
    Blumhardt, L
    Lilliu, H
    Beresniak, A
    CLINICAL DRUG INVESTIGATION, 2003, 23 (09) : 571 - 581
12345